Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Alberta Investment Management Corp raised its holdings in Neurocrine Biosciences by 10.4% during the 2nd quarter.
As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 2.17 EPS for the current year.
As a group, sell-side analysts predict that Neurocrine Biosciences will post 2.2 EPS for the current fiscal year.
Brown Advisory Inc. increased its holdings in Neurocrine Biosciences by 0.5% in the 3rd quarter.
Cantor Fitzgerald reaffirmed an “overweight” rating and set a $136.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday.
Congress Asset Management Co. MA raised its holdings in Neurocrine Biosciences by 1.9% in the third quarter.
Dupont Capital Management Corp reduced its stake in shares of Neurocrine Biosciences, Inc. () by 15.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
Finally, raised Neurocrine Biosciences from a buy rating to a strong-buy rating in a report on Thursday, December 7th.
HC Wainwright reaffirmed a “buy” rating and set a $140.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday.
Morgan Stanley upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $120.00 to $130.00 in a research report on Friday, February 3rd.
Neurocrine Biosciences had a net margin of 4.19% and a return on equity of 4.06%.
The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through William H. Rastetter sold 903 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, April 19th.